
Novo Nordisk to Buy Hypertension Treatment from KBP Biosciences
Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to $1.3 billion.